The research collaboration agreement includes an option to license DSM's bioerodible polymer implant technology for evaluating its application to the delivery of certain Aerie compounds, initially focused on retinal diseases. DSM's technology uses polyesteramide polymers (PEA) to produce an injectable, thin fiber that is minute in size. Preclinical experiments have demonstrated early success in conjunction with Aerie compounds, including demonstration of linear sustained elution rates over several months and achievement of target retinal drug concentrations.
Aerie previously reported data on Aerie-owned small molecule preclinical product candidate AR-13154, which inhibits Rho kinase and Protein kinase C and thus addresses vascular dysfunction, fibrosis, and inflammation. This molecule has generated lesion size decreases in a preclinical model of wet AMD (age-related macular degeneration) at levels similar to the market-leading wet AMD anti-VEGF product, and has generated meaningful incremental lesion size reduction when added adjunctively to the anti-VEGF product. Preclinical studies also demonstrated the promising potential of this molecule to reduce neovascularization in a model of proliferative diabetic retinopathy. Pending additional studies, AR-13154 and related compounds may have the potential to provide an entirely new mechanism and pathway to treat these diseases.
"A key to unlocking the potential of AR-13154 and related Aerie-owned
compounds for the treatment of retinal diseases is the identification of
the appropriate technology to achieve longer-term sustained delivery of
our small molecules to the back of the eye. We are hopeful that DSM's
PEA technology may prove to be that technology," said
The terms of the agreement with DSM were not disclosed and the agreement is immaterial to Aerie based on the level of current financial commitments.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two current product candidates are once-daily intraocular
pressure lowering therapies with novel mechanisms of action to treat
patients with glaucoma or ocular hypertension. The NDA (new drug
application) for RhopressaTM (netarsudil ophthalmic solution)
0.02% was submitted to the
DSM - Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition,
and materials. By connecting its unique competences in life sciences and
materials sciences DSM is driving economic prosperity, environmental
progress, and social advances to create sustainable value for all
stakeholders simultaneously. DSM delivers innovative solutions that
nourish, protect, and improve performance in global markets such as food
and dietary supplements, personal care, feed, medical devices,
automotive, paints, electrical and electronics, life protection,
alternative energy, and bio-based materials. DSM and its associated
companies deliver annual net sales of about €10 billion with
approximately 25,000 employees. The company is listed on
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"will," "should," "exploring," "pursuing" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: the
success, timing and cost of our ongoing and anticipated preclinical
studies and clinical trials for our current and potential future product
candidates, including statements regarding the timing of initiation and
completion of the studies and trials; our expectations regarding the
clinical effectiveness of our product candidates and results of our
clinical trials; the timing of and our ability to request, obtain and
News Provided by Acquire Media